The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy in
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.
Patients in the TRANSCEND FL study received liso-cel after lymphodepleting chemotherapy (LDC). Bridging therapy was allowed with reconfirmation of PET-positive disease before LDC. The primary endpoint was overall response rate (ORR) per independent review committee by PET/CT using Lugano 2014 criteria
Prof. Charlie Craddock, CBE, discusses what to expect at the first SOHO UK, which will be held 3–4 March 2026 in London at the Royal
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to standard chemotherapy
To access the SOHO Career Center click the following link.
